A common treatment after a heart attack is the reopening of the blocked coronary artery to restore the blood flow. This is what experts call reperfusion therapy, which has greatly reduced mortality of patients. However, many survivors end up with large infarct areas that compromise cardiac function in the long-term. 

The PhotoHeart project aims to provide early and localized treatment at the time of reperfusion therapy to significantly reduce cardiac tissue damage, thus boosting patient recovery and minimizing future cardiac conditions. To this end, the MCS team led by Amadeu Llebaria, from IQAC-CSIC, in collaboration with teams from VHIR and Johns Hopkins University, is developing a photopharmacological therapy that will allow light-controlled drugs to be administered and only activated in the area most affected by reperfusion therapy by attaching a light device to the catheter used to open the arteries. 

Fulletó en català

Folleto en castellano

This R+D+I meeting will brought together researchers, entrepreneurs and the pharma industry interested in photopharmacology research, as well as in the transfer of research results to the market and the development of associated medical devices.